Analysis of the inflammatory process and insulin resistance in the gastrocnemius muscle of non-obese Type 2 Diabetic Goto-kakizaki rats supplemented with omega-3

• Grant number: 24/05095-4
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: July 01, 2024
• End date: December 31, 2025
• Field of knowledge: Biological Sciences - Physiology - Physiology of Organs and Systems
• Principal Investigator: Sandro Massao Hirabara
• Grantee: Isabele da Silva Ramos
• Host Institution: Centro de Ciências Biológicas e da Saúde. Universidade Cruzeiro do Sul (UNICSUL). São Paulo , SP, Brazil
• Associated research grant: 18/09868-7 - Cellular and molecular mechanisms of insulin resistance and inflammation in obese Wistar rats and lean Goto-Kakizaki rats: causes and associations with diet and physical exercise, AP.TEM

Abstract

Type 2 diabetes mellitus is a chronic disease that affects people all over the world and in different social classes, where insulin resistance (IR) develops. Due to the progression of the disease, several organs are affected, including skeletal muscle. Given this fact and the need to obtain new therapeutic targets, we developed work with omega-3 supplementation in non-obese type 2 diabetic Goto-Kakizaki rats, compared with Wistar rats. The objective of this study is to characterize the molecular mechanisms involved in insulin sensitivity signaling and the inflammatory process in the gastrocnemius of Goto-Kakizaki rats supplemented with omega-3. Our preliminary results confirmed, as in work carried out by the group, the result of insulin resistance and non-obesity in the Goto-Kakizaki rat. The hypothesis to be tested is that the gastrocnemius skeletal muscle of non-obese type 2 diabetic Goto-Kakizaki animals (GK) supplemented with omega-3 with peripheral insulin resistance is a good tissue to analyze insulin resistance and the process inflammation with omega-3 supplementation. These results will allow the development of strategies to better direct the group's future work, contributing to therapeutic alternatives in the treatment of type 2 diabetes.